Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py in Chi­na

May 16, 2025 – Cy­ti­va and Eu­re­ka Biotech­nol­o­gy, Ltd (Eu­rek­aBio) to­day an­nounced a strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor (LVV) man­u­fac­tur­ing in Chi­na. The col­lab­o­ra­tion cen­ters on Eu­rek­aBio’s pro­pri­etary Eu­LV™ lentivi­ral vec­tor sta­ble pro­duc­er cell line pro­duc­tion sys­tem with the goal of com­bin­ing the com­pa­nies’ strengths and re­sources to dri­ve in­no­va­tion in vi­ral vec­tor man­u­fac­tur­ing for the rapid­ly grow­ing cell and gene ther­a­py (CGT) sec­tor.

As CGT tech­nolo­gies progress, the de­mand for re­li­able, cost-ef­fec­tive vi­ral vec­tor man­u­fac­tur­ing so­lu­tions has be­come in­creas­ing­ly crit­i­cal. Eu­rek­aBio’s Eu­LV™sys­tem pro­vides a ro­bust al­ter­na­tive to con­ven­tion­al tran­sient trans­fec­tion meth­ods, of­fer­ing a scal­able, ef­fi­cient, and eco­nom­i­cal­ly vi­able ap­proach to LVV pro­duc­tion. Key ad­van­tages of the Eu­LV™sys­tem in­clude:

• Sim­pli­fied process: Elim­i­nates the need for GMP-grade plas­mids through a sta­ble pro­duc­er cell line ap­proach.
• Cost ef­fi­cien­cy: Re­duces re­liance on plas­mids and trans­fec­tion reagents, while de­liv­er­ing high pro­duc­tiv­i­ty.
• Scal­a­bil­i­ty: En­ables high-den­si­ty sus­pen­sion cul­ture, ide­al for large-scale man­u­fac­tur­ing.
• Con­sis­tent qual­i­ty: Us­es well-char­ac­ter­ized pro­duc­er cells with high uni­for­mi­ty and min­i­mal batch-to-batch vari­a­tion.

Through this strate­gic al­liance, Cy­ti­va and Eu­rek­aBio will em­pow­er bio­phar­ma­ceu­ti­cal com­pa­nies to in­te­grate Eu­rek­aBio’s pro­pri­etary Eu­LV™ sys­tem in­to their ad­vanced work­flows, en­abling scal­able, GMP-com­pli­ant man­u­fac­tur­ing of ad­vanced cell and gene ther­a­pies. Un­der the agree­ment, Cy­ti­va will se­cure ex­clu­sive sub-li­cens­ing rights to the patent­ed Eu­LV™ tech­nol­o­gy and ex­e­cute com­pre­hen­sive li­cens­ing ser­vices across Chi­na. To­geth­er, the two par­ties will pur­sue mile­stone-based li­cens­ing agree­ments with bio­phar­ma part­ners, en­sur­ing ac­cess to strong, en­force­able in­tel­lec­tu­al prop­er­ty pro­tec­tions that align with glob­al reg­u­la­to­ry re­quire­ment.

Lo­cal­ized cell bank­ing for ac­cel­er­at­ed drug de­vel­op­ment

Cy­ti­va’s Chi­na In­no­va­tion Cen­ter will lever­age its lo­cal­ized process de­vel­op­ment ex­per­tise and end-to-end CGT in­dus­try ex­pe­ri­ence to es­tab­lish and main­tain Mas­ter Cell Banks (MCB) and Work­ing Cell Banks (WCB) for the Eu­LV™pack­ag­ing cell line in Chi­na. These cell banks com­ply with both Chi­nese and U.S. GMP stan­dards, sup­port­ing pre­clin­i­cal stud­ies, clin­i­cal tri­als, reg­u­la­to­ry sub­mis­sions, and com­mer­cial pro­duc­tion. By of­fer­ing shared, ready-to-use cell banks, the col­lab­o­ra­tion aims to re­duce costs and ac­cel­er­ate drug de­vel­op­ment for bio­phar­ma com­pa­nies.

Syn­er­gy for in­dus­try trans­for­ma­tion

Dri­ven by its mis­sion to “Ex­pand the Fron­tiers of Treat­ment,” Eu­rek­aBio is ded­i­cat­ed to ad­vanc­ing cell and gene ther­a­py (CGT) tech­nolo­gies and en­abling their in­dus­tri­al-scale ap­pli­ca­tion. Through the in­te­gra­tion of its Eu­LV™ Sys­tem with Cy­ti­va’s glob­al ca­pa­bil­i­ties, this col­lab­o­ra­tion aims to ad­dress crit­i­cal tech­ni­cal and eco­nom­ic chal­lenges in vi­ral vec­tor man­u­fac­tur­ing, ul­ti­mate­ly ac­cel­er­at­ing the de­vel­op­ment of Cell & Gene ther­a­pies from lab to clin­ic.

In the era of CGT in­dus­tri­al­iza­tion, true progress re­quires both tech­no­log­i­cal ex­cel­lence and ecosys­tem vi­sion. This part­ner­ship ex­em­pli­fies Eu­rek­aBio’s un­wa­ver­ing com­mit­ment to in­no­va­tion and col­lab­o­ra­tion—demon­strat­ing the strength of its plat­form against glob­al stan­dards while re­main­ing deeply at­tuned to the needs of the lo­cal in­dus­try. Through con­tin­u­ous process op­ti­miza­tion and strate­gic al­liances, Eu­rek­aBio re­in­forces its mis­sion to “re­duce costs, en­hance ef­fi­cien­cy, and de­liv­er life-chang­ing ther­a­pies to pa­tients world­wide.”

About Eu­rek­aBio:
Eu­rek­aBio is a lead­ing up­stream tech­nol­o­gy in­no­va­tor in the cell and gene ther­a­py (CGT) space, ded­i­cat­ed to the in­de­pen­dent de­vel­op­ment of core tech­nolo­gies and spe­cial­ized equip­ment. By bridg­ing life sci­ences with ex­per­tise in com­put­er sci­ence, elec­tron­ics, nano­ma­te­ri­als, and chem­i­cal en­gi­neer­ing, Eu­rek­aBio has de­vel­oped next-gen­er­a­tion tools and plat­forms to ad­dress crit­i­cal chal­lenges in gene ther­a­py, cell ther­a­py, and phar­ma­ceu­ti­cal R&D, ad­vanc­ing the fron­tiers of ther­a­peu­tic in­no­va­tion.

About Cy­ti­va:
Cy­ti­va is a glob­al life sci­ences leader, em­ploy­ing ap­prox­i­mate­ly 15,000 peo­ple across more than 40 coun­tries. Ded­i­cat­ed to ad­vanc­ing break­through tech­nolo­gies and ac­cel­er­at­ing life-chang­ing ther­a­pies, Cy­ti­va part­ners with re­searchers, biotech de­vel­op­ers, and man­u­fac­tur­ers to sup­port de­vel­op­ment in bio­phar­ma­ceu­ti­cals, cell and gene ther­a­pies, and mR­NA-based tech­nolo­gies. By en­hanc­ing the ca­pa­bil­i­ty, speed, and flex­i­bil­i­ty of bio­pro­cess­ing, Cy­ti­va helps bring trans­for­ma­tive med­i­cines to pa­tients around the world.